Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jul;21(7):1752-1756.
doi: 10.1111/dom.13729. Epub 2019 Apr 23.

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes

Anne L Peters  1 , Milivoj Piletič  2 , Johan Ejstrud  3 , Karen Salvesen-Sykes  4 , James Snyder  4 , Keith Bowering  5
Affiliations
Randomized Controlled Trial

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes

Anne L Peters et al. Diabetes Obes Metab. 2019 Jul.

Abstract

This post hoc analysis of an 18-week randomized trial explored the utility of calculating baseline glycated haemoglobin (HbA1c), postprandial glucose (PPG) increments and nocturnal glucose change in predicting efficacy and safety outcomes in response to bolus insulin intensification in people with type 2 diabetes (T2D). Analyses were conducted on 236 participants with T2D receiving metformin: 116 received fast-acting insulin aspart (faster aspart) basal-bolus therapy and 120 received basal-only insulin. Participants were grouped according to baseline HbA1c, PPG increments and nocturnal glucose change variables; analyses were performed on the end-of-trial treatment differences between "high" and "low" baseline values. The change from baseline in end-of-trial mean HbA1c and mean PPG increments was in favour of faster aspart across all subgroups. Significantly greater treatment differences were observed in participants with high (vs. low) baseline nocturnal glucose change and PPG increments. For baseline HbA1c, significantly greater treatment differences were observed for change in end-of-trial PPG increments, but not end-of-trial HbA1c. In conclusion, both nocturnal glucose change and PPG increments may be more useful than HbA1c for identifying subgroups of people with T2D who would most benefit from bolus intensification.

Keywords: clinical trial; insulin therapy; randomized trial; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

A.L.P. has served on advisory boards for Abbott Diabetes Care, Becton Dickinson, Bigfoot, Eli Lilly and Company, Lexicon, Livongo, Mannkind, Medscape, Merck, Novo Nordisk, Omada Health, Sanofi and Zafgen, has served on a speakers' bureau for Novo Nordisk and received research funding from AstraZeneca, Dexcom and Mannkind. M.P. has participated in advisory panels for Novo Nordisk, Boehringer Ingelheim and Eli Lilly. J.E. is an employee of and holds stock in Novo Nordisk. K.S.‐S. is an employee of and holds shares in Novo Nordisk. J.S. is an employee of and holds stock in Novo Nordisk. K.B. has participated in advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, and speakers' bureau for Novo Nordisk and Sanofi.

Figures

Figure 1
Figure 1
Change from baseline in glycated haemoglobin (HbA1c) at week 18, stratified by baseline variables. *Negative values are in favour of fast‐acting insulin aspart (faster aspart). **Statistically significant difference between estimated treatment difference (ETD) reported in the “high” and “low” subgroups. CI, confidence interval; PPG, postprandial glucose
Figure 2
Figure 2
Change from baseline in mean postprandial glucose (PPG) increment at week 18, stratified by baseline variables. *Negative values are in favour of fast‐acting insulin aspart (faster aspart). **Statistically significant difference between estimated treatment difference (ETD) reported in “high” and “low” subgroups. CI, confidence interval; HbA1c, glycated haemoglobin
See this image and copyright information in PMC

References

    1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405‐412. - PMC - PubMed
    1. American Diabetes Association . Standards of Medical Care in Diabetes–2018. Diabetes Care. 2018;41:S1‐S155. - PubMed
    1. Owens DR, Traylor L, Dain MP, Landgraf W. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat‐to‐target randomised controlled trials. Diabetes Res Clin Pract. 2014;106:264‐274. - PubMed
    1. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280‐285. - PubMed
    1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881‐885. - PubMed

Publication types

MeSH terms